Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
On the contrary, -cell mass in an advanced phase was drastically reduced in all groups compared to an early phase (Fig
When a biosimilar enters at a 30-50% discount to the reference product, the national payer has both the authority and the economic incentive to mandate or strongly incentivize its use
Masi A, DeMayo MM, Glozier N, Guastella AJ (2017) An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Do not freeze reconstituted product
US$ 22.69
US$ 26.15
US$ 29.26
:format(webp))
US$ 20.46
